Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTx1000 in Amyotrophic Lateral Sclerosis
NCT07401121Phase 1Recruiting
- Sponsor
- Celosia Therapeutics
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CTx1000 in amyotrophic lateral sclerosis (ALS), sponsored by Celosia Therapeutics. Primary endpoint: Safety and Tolerability at 52 weeks. Started Jan 2026; status: recruiting.
02
Drugs
CTx1000
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT07401121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07401121.